



Taking the **NEXT STEPS** in Alzheimer's Disease:

Future Improvements in Diagnosis and Treatment

Friday, March 2, 2007

12:00 PM – 12:30 PM Lunch
12:30 PM – 2:00 PM Scientific Session

**The Sheraton
New Orleans Hotel**

5th Floor – Grand Ballroom D/E

sanofi aventis

Supported by an
educational grant from
sanofi-aventis U.S.

Agenda and Faculty

Prevalence of AD: A Growing Crisis

Stephen Salloway, MD, MS
Program Chair
Director of Neurology
Director, Memory and Aging Program
Butler Hospital
Professor of Clinical Neurosciences and Psychiatry
Brown Medical School
Providence, Rhode Island

Early Identification of AD Patients: What We Know About MCI

Howard Feldman, MD, CM, FRCP(C)
Professor and Head, Division of Neurology
University of British Columbia
Director, Clinic for Alzheimer Disease & Related Disorders
UBC Hospital
Vancouver, British Columbia, Canada

Taking the Next Steps in Diagnosis of AD: The Use of Biomarkers

Steven DeKosky, MD
Professor and Chair
Department of Neurology
Director, Alzheimer's Disease Research Center
University of Pittsburgh
Pittsburgh, Pennsylvania

Taking the Next Steps in Treatment of AD: Disease-Modifying Agents

Stephen Salloway, MD, MS
Program Chair

Question and Answer Session
Faculty



Provided by the
American Association
for Geriatric Psychiatry.



Friday, March 2, 2007

12:00 pm – 2:00 pm

The Sheraton New Orleans Hotel

5th Floor – Grand Ballroom D/E

Program Overview

Alzheimer's disease (AD) is the most prevalent neurological disorder, afflicting over 4.5 million people in the US alone (Alzheimer's Disease Fact Sheet; www.alz.org). As the number of elderly people continues to grow steadily, the prevalence of AD is expected to at least triple by the year 2050, making it one of the nation's most overwhelming and concerning health crises. In order to relieve the personal, economic, and healthcare burden created by this disease, it is critical that advances in the recognition, diagnosis, and treatment of AD be made.

Learning Objectives

At the completion of this program, participants should be better able to:

- Understand the relationship between mild cognitive impairment (MCI) and AD
- Discuss recent developments in the diagnosis of AD
- Consider the future of AD treatment

Accreditation Information

The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Association for Geriatric Psychiatry designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This symposium is open to all attendees who have paid a registration fee to attend the AAGP's 2007 Annual Meeting. Seating will be on a first-come, first-served basis.

Cerebrio

220 East 42nd Street

5th Floor

New York, NY 10017

